key: cord-0721193-cs076ske
authors: Athyros, Vasilios G.; Stavropoulos, Konstantinos; Imprialos, Konstantinos P.; Doumas, Michael
title: Suboptimal management of dyslipidemia in everyday clinical practice: Alarming signals from real-world data
date: 2020-07-04
journal: Int J Cardiol
DOI: 10.1016/j.ijcard.2020.06.059
sha: 273ddad5caac1565cd34d360eb4ece1de43a8010
doc_id: 721193
cord_uid: cs076ske

nan

J o u r n a l P r e -p r o o f 4 estimated that approximately 20% of patients on high-intensity statin achieved a LDL-c <55 mg/dl along with half a reduction in LDL-c level, which increased up to 49% with the addition of ezetimibe.

Of great interest, when use of PCSK9 inhibitors was simulated in eligible participants (50.6%), approximately 90% attained the LDL-c target. However, with respect to limited resources in healthcare systems, especially after the COVID-19 pandemic, the cost-effectiveness of this approach in a population-based level is rather warranted [2] .

The insufficient management of dyslipidemia in everyday clinical practice poses a meaningful healthcare aspect and might result in detrimental cardiovascular outcomes. Relevant scientific authorities need to investigate this problem in depth and take action to improve the management of dyslipidemia. Future well-designed randomized controlled trials will elucidate whether a LDL-c goal <55 mg/dl is feasible without the use of PCSK9 inhibitors, overcoming the high cost of new therapies.

Older lipid guidelines needed a 10-year period to be implemented by the majority of physicians in clinical practice. Lets hope that the new guidelines will START to be implemented much earlier. 

Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG)

ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk

A Clinical Perspective on the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: PCSK-9 Inhibitors for All?

the START Investigators. Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS Guidelines in very highrisk patients with established atherosclerotic cardiovascular disease: Insights from the START Registry

Healthcare resource utilization in patients on lipid-lowering therapies outside Western Europe and North America: findings of the cross-sectional observational International ChoLesterol management Practice Study (ICLPS)

Lifetime risk assessment in cholesterol management among hypertensive patients: observational crosssectional study based on electronic health record data

Low-density lipoprotein cholesterol goal attainment rates in high-risk patients with cardiovascular diseases and diabetes mellitus in Korea: a retrospective cohort study

Simplifying the Audit of Risk Factor Recording and Control: A

Application of the 2019 ESC/EAS Dyslipidaemia Guidelines to Nationwide Data of Patients With a Recent Myocardial Infarction: A Simulation Study